vida: extract claims from 2026-04-22-kff-poll-1-in-8-glp1-affordability-gap

- Source: inbox/queue/2026-04-22-kff-poll-1-in-8-glp1-affordability-gap.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -32,3 +32,10 @@ Nearly 4 in 10 adults and a quarter of children with Medicaid have obesity, repr
 **Source:** KFF Medicaid GLP-1 Coverage Analysis, January 2026
 
 The Medicaid population has the highest obesity burden (40% of adults, 25% of children) but only 26% of state programs provide coverage. Even where covered, GLP-1s are 'typically subject to utilization controls such as prior authorization,' creating additional access barriers for the population with least ability to pay out of pocket.
+
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+KFF national poll finds only 23% of obese/overweight adults currently taking GLP-1s, creating a 77% access gap among the eligible population. Among current users, 56% report difficulty affording medications, and 27% of insured users paid full cost out-of-pocket. The age 65+ population shows only 9% uptake, directly reflecting Medicare's statutory exclusion of weight-loss drugs. Cost-driven discontinuation (14%) rivals side effect discontinuation (13%) as a cessation driver.

domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md

@@ -10,17 +10,17 @@ agent: vida
 scope: structural
 sourcer: RGA (Reinsurance Group of America)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier]]"]
-supports:
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
-- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
-reweave_edges:
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
-- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes"]
+reweave_edges: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
 ---
 
 # GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
 
-The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).
+The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+Population-level penetration data shows 77% of eligible obese/overweight adults are not taking GLP-1s despite drug availability. Among those with diagnosed conditions showing highest benefit potential, uptake remains limited: 45% of diabetes patients, 29% of heart disease patients, and only 23% of obese/overweight adults currently using. The Medicare-eligible population (65+) shows lowest uptake at 9%, despite highest disease burden.

domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md

@@ -25,3 +25,10 @@ The Lancet February 2026 editorial provides highest-prestige institutional frami
 # GLP-1 anti-obesity drug access is structurally inverted: populations with greatest cardiovascular mortality risk face the highest costs and lowest coverage rates, preventing clinical efficacy from reaching population-level impact
 
 ICER's 2025 access analysis reveals a structural inversion: the populations with greatest cardiovascular mortality risk (lower SES, Black Americans, Southern rural residents) face the highest out-of-pocket costs and lowest insurance coverage rates for GLP-1 anti-obesity medications. In Mississippi, continuous GLP-1 treatment costs approximately 12.5% of annual income for the typical individual. Only 19% of US employers with 200+ workers cover GLP-1s for weight loss (2025 data). Most critically, California Medi-Cal—the largest state Medicaid program—ended coverage of GLP-1 medications prescribed solely for weight loss effective January 1, 2026, exactly when clinical evidence for cardiovascular mortality benefit is strongest (SELECT trial FDA approval March 2024). This is not a temporary access gap but a structural misalignment: the regulatory/coverage system is moving opposite to the clinical evidence direction. The drugs have proven individual-level efficacy for cardiovascular mortality reduction, but access concentration in low-risk, higher-income populations means clinical efficacy cannot translate to population-level impact on the timeline suggested by individual trial results. This explains the RGA 2045 projection for population-level mortality impact despite 2024 clinical proof of individual benefit.
+
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+Among populations with highest cardiovascular benefit potential, GLP-1 uptake remains constrained: 29% of heart disease patients currently using, while 56% of current users across all indications report affordability difficulties. The age 65+ population with highest CVD risk shows only 9% uptake due to Medicare exclusion structure.

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -1,31 +1,15 @@
 ---
 type: claim
 domain: health
-description: "Income level correlates with GLP-1 discontinuation rates in commercially insured populations, indicating that cost-sharing and affordability barriers drive adherence as much as clinical factors like side effects or insufficient weight loss"
+description: Income level correlates with GLP-1 discontinuation rates in commercially insured populations, indicating that cost-sharing and affordability barriers drive adherence as much as clinical factors like side effects or insufficient weight loss
 confidence: experimental
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-related_claims:
-  - divergence-glp1-economics-chronic-cost-vs-low-persistence
-related:
-- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings
-- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints
-- pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling
-- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months
-- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
-reweave_edges:
-- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31
-- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31
-- pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31
-- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14
-- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17
-supports:
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
-- GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
-sourced_from:
-- inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md
+related_claims: ["divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"]
+reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17"]
+supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs"]
+sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
 ---
 
 # Lower-income patients show higher GLP-1 discontinuation rates suggesting affordability not just clinical factors drive persistence
@@ -90,4 +74,10 @@ Relevant Notes:
 - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
 
 Topics:
-- domains/health/_map
+- domains/health/_map
+
+## Supporting Evidence
+
+**Source:** KFF Poll 2025
+
+Among current GLP-1 users, 56% report difficulty affording medications, with 27% of insured users paying full out-of-pocket cost. Cost-driven discontinuation (14% of former users) equals side effect discontinuation (13%), establishing affordability as a primary persistence barrier independent of clinical tolerance.